ReviewSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society2026
The biological functions of monoacylglycerol lipase (MAGL) in cancer.
Review in Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is a metabolic disease marked by disruptions in lipid metabolism, which significantly influences tumor development. The synthesis and breakdown of lipids, governed by various enzymes, play a vital role in this process. One notable enzyme, monoacylglycerol lipase (MAGL), hydrolyzes monoacylglycerides into glycerol and free fatty acids, thereby generating protumorigenic lipid-signaling molecules that facilitate tumor growth and malignancy. MAGL's primary substrate, 2-arachidonoylglycerol, acts as an agonist for endocannabinoid receptors and serves as a precursor for arachidonic acid, which is critical in producing pro-inflammatory mediators, such as prostaglandins. Dysregulation of MAGL expression has been associated with various cancer types. This review summarizes current knowledge of MAGL's role in cancer progression and proposes MAGL as a promising target for cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.